Patents by Inventor Robert Preti

Robert Preti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • A CLOSED SYSTEM FOR LABELLING AND SELECTING LIVE CELLS
    Publication number: 20190099540
    Abstract: The described invention provides an automated, closed system and method for separating/isolating a target cell type from a heterogeneous cell population.
    Type: Application
    Filed: March 27, 2017
    Publication date: April 4, 2019
    Applicants: HITACHI CHEMICAL ADVANCED THERAPEUTICS SOLUTIONS, LLC, HITACHI CHEMICAL ADVANCED THERAPEUTICS SOLUTIONS, LLC
    Inventors: David Smith, Wai Shun Chan, Brian Hampson, Robert Preti, Yajuan Jiang, Courtney Leblon
  • HUMAN VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS FOR TREATMENT OF OCULAR DISEASE
    Publication number: 20160022743
    Abstract: The present invention relates to use of very small embryonic-like (VSEL) stem cells in therapies for ocular disease involving retinal degeneration or dysfunction. The invention also included pharmaceutical compositions made with VSELs which may be used to restore lost vision or reduce or halt vision loss due to diseases or disorders of the retina, or other diseases or retinal injuries that would benefit from stem cell replacement therapy.
    Type: Application
    Filed: May 31, 2013
    Publication date: January 28, 2016
    Applicant: The Schepens Eye Research Institute, Inc.
    Inventors: Kameran LASHKARI, Michael YOUNG, Sarah EMINLI-MEISSNER, Wayne MARASCO, Robert PRETI
  • Infarct area perfusion-improving compositions and methods of vascular injury repair
    Patent number: 9034316
    Abstract: The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: May 19, 2015
    Assignee: Amorcyte, LLC
    Inventors: Andrew Pecora, Robert Preti
  • Compositions and methods of vascular injury repair
    Patent number: 8088370
    Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of cells having chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: January 3, 2012
    Assignee: Amorcyte, Inc.
    Inventors: Andrew Pecora, Robert Preti
  • INFARCT AREA PERFUSION-IMPROVING COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR
    Publication number: 20100143317
    Abstract: The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.
    Type: Application
    Filed: December 2, 2009
    Publication date: June 10, 2010
    Inventors: Andrew Pecora, Robert Preti
  • Compositions and Methods of Vascular Injury Repair
    Publication number: 20090226402
    Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of cells having chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.
    Type: Application
    Filed: March 10, 2009
    Publication date: September 10, 2009
    Inventors: Andrew Pecora, Robert Preti
  • COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR
    Publication number: 20070105217
    Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of cells having chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.
    Type: Application
    Filed: October 24, 2006
    Publication date: May 10, 2007
    Inventors: Andrew Pecora, Robert Preti